Our data not only expand our understanding of the relationship between drug resistance and cancer metabolism, especially in the FOCM pathway, but also indicate that ALDH1L2 K70 could be a potential therapeutic site to prevent drug resistance. Here, ALDH1L2 is linked to cancer.